Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Identification of tumour necrosis factor apoptosis inducing ligand (TRAIL), a TNF family ligand, sparked a torrent of research, following an initial observation that it could kill tumour cells, but spare normal cells. Almost a decade after its discovery, and with five known receptors, the true physiological role of TRAIL is still debated and its anti-tumorigenic properties limited by potential toxicity. This review takes a comprehensive look at the story of this enigmatic ligand, addressing its remaining potential as a therapeutic and providing an overview of the TRAIL receptors themselves.

Original publication

DOI

10.1038/sj.cr.7290236

Type

Journal article

Journal

Cell Res

Publication Date

10/2004

Volume

14

Pages

359 - 372

Keywords

Animals, Apoptosis, Apoptosis Regulatory Proteins, Humans, Ligands, Membrane Glycoproteins, Models, Biological, Protein Structure, Tertiary, Receptors, Tumor Necrosis Factor, TNF-Related Apoptosis-Inducing Ligand, Tumor Necrosis Factor-alpha